Due to space limitations in the exclusivity
column, the following abbreviations have been developed. please
refer to this page for an explanation of the patent and
exclusivity abbreviations found in the addendum.
| I-1 |
DYSMENORRHEA |
| I-2 |
CHOLANGIOPANCREATOGRAPHY |
| I-3 |
INTRAVENOUS
DIGITAL SUBTRACTION ANGIOGRAPHY |
| I-4 |
PERIPHERAL
VENOGRAPHY (PHLEBOGRAPHY) |
| I-5 |
HYSTEROSALPINGOGRAPHY |
| I-6 |
TREATMENT
OF JUVENILE ARTHRITIS |
| I-7 |
BIOPSY
PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN |
| I-8 |
ADULT
INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE
HEAD AND BODY |
| I-9 |
PREVENTION
OF POSTOPERATIVE NAUSEA AND VOMITING |
| I-10 |
PREVENTION
OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY
EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY |
| I-11 |
RELIEF OF
MILD TO MODERATE PAIN |
| I-12 |
TREATMENT
OF CUTANEOUS CANDIDIASIS |
| I-13 |
URINARY
TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE
MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI |
| I-14 |
SEBORRHEIC
DERMATITIS |
| I-15 |
PHOTOPHERESIS
IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF
CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO
OTHER TREATMENT |
| I-16 |
STIMULATE
THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN
OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO
FERTILIZATION PROGRAM |
| I-17 |
MANAGEMENT
OF CONGESTIVE HEART FAILURE |
| I-18 |
ENDOSCOPIC
RETROGRADE PANCREATOGRAPHY |
| I-19 |
HERNIOGRAPHY |
| I-20 |
KNEE
ARTHROGRAPHY |
| I-21 |
HIGH DOSE
METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH
OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN
PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE
UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE
PRIMARY TUMOR |
| I-22 |
RESCUE
AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA |
| I-23 |
SHORT-TERM
TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
| I-24 |
TREATMENT
OF RHEUMATOID ARTHRITIS |
| I-25 |
ADULT
INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE
HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS |
| I-26 |
TREATMENT
OF LIVER FLUKES |
| I-27 |
ADJUNCTIVE
THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY
DISEASE |
| I-28 |
SELECTIVE
ADULT VISCERAL ARTERIOGRAPHY |
| I-29 |
METASTATIC
BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO
OOPHORECTOMY OR OVARIAN IRRADIATION |
| I-30 |
TREATMENT
OF TINEA PEDIS |
| I-31 |
CONTRAST
ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS
IN THE SPINE AND ASSOCIATED TISSUES |
| I-32 |
PEDIATRIC
MYELOGRAPHY |
| I-33 |
ORAL USE
OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST
ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN |
| I-34 |
ORAL USE
IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE
GASTROINTESTINAL TRACT |
| I-35 |
PEDIATRIC
CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING |
| I-36 |
ARTHROGRAPHY
OF THE SHOULDER JOINTS IN ADULTS |
| I-37 |
RADIOGRAPHY
OF THE TEMPOROMANDIBULAR JOINT IN ADULTS |
| I-38 |
CONTRAST
ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS
OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE
AND OLDER) |
| I-39 |
TREATMENT
OF ACUTE MYOCARDIAL INFARCTION |
| I-40 |
PRIMARY
NOCTURNAL ENURESIS |
| I-41 |
MIGRAINE
HEADACHE PROPHYLAXIS |
| I-42 |
HERPES
ZOSTER |
| I-43 |
HERPES
SIMPLEX ENCEPHALITIS |
| I-44 |
MAINTENANCE
THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1
GRAM TWICE DAILY |
| I-45 |
ACUTE
TREATMENT OF VARICELLA ZOSTER VIRUS |
| I-46 |
USE IN
PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING |
| I-47 |
TREATMENT
OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN
IMMUNODEFICIENCY VIRUS (HIV) DISEASE |
| I-48 |
PEDIATRIC
ANGIOCARDIOGRAPHY |
| I-49 |
TREATMENT
OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF
ENTEROTOXIGENIC ESCHERICHIA COLI |
| I-50 |
FOR USE IN
WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER |
| I-51 |
TREATMENT
OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF
IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS |
| I-52 |
PEDIATRIC
EXCRETORY UROGRAPHY |
| I-53 |
TREATMENT
OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA |
| I-54 |
RENAL
CONCENTRATION CAPACITY TEST |
| I-55 |
HYPERTENSION |
| I-56 |
EROSIVE
GASTROESOPHAGEAL REFLUX DISEASE |
| I-57 |
SHORT-TERM
TREATMENT OF ACTIVE DUODENAL ULCER |
| I-58 |
INITIAL
TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION
WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS |
| I-59 |
ENDOSCOPICALLY
DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE
ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO
GASTROESOPHAGEAL REFLUX DISEASE |
| I-60 |
SINGLE
APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS
TO TWO YEARS IN AGE |
| I-61 |
FEMALE
ANDROGENETIC ALOPECIA |
| I-62 |
PREVENTION
AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| I-63 |
ONCE DAILY
TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF
HYPERTENSION |
| I-64 |
PREVENTION
OF SUPRAVENTRICULAR TACHYCARDIAS |
| I-65 |
PREVENTION
OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL
PATIENTS |
| I-66 |
UNCOMPLICATED
GONORRHEA |
| I-67 |
TREATMENT
OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE
AND OLDER |
| I-68 |
CENTRAL
PRECOCIOUS PUBERTY |
| I-69 |
SHORT TERM
TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL
REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT
OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE
DIAGNOSED BY ENDOSCOPY |
| I-70 |
USE IN
COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN
THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED
COLORECTAL CANCER |
| I-71 |
VARICELLA
INFECTIONS (CHICKENPOX) |
| I-72 |
PREVENTION
OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV
DISEASE |
| I-73 |
INITIATE
AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION
DURING DIAGNOSTIC PROCEDURES |
| I-74 |
INTRAVENOUS
DIGITAL SUBTRACTION ANGIOGRAPHY |
| I-75 |
TREATMENT
OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS |
| I-76 |
PREVENTION
OF OSTEOPOROSIS |
| I-77 |
DERMAL
INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE
TO EPIDERMOPHYTON FLOCCOSUM |
| I-78 |
CONTRAST
ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND
BODY AND INTRAVENOUS EXCRETORY UROGRAPHY |
| I-79 |
MANAGEMENT
OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY
ARTERY SPASM |
| I-80 |
DIAGNOSIS
AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE |
| I-81 |
PROPHYLAXIS
IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE
INCIDENCE OF OROPHARYNGEAL CANDIDIASIS |
| I-82 |
TREATMENT
OF TRAVELERS' DIARRHEA |
| I-83 |
ANGIOCARDIOGRAPHY,
CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE
HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN
CHILDREN |
| I-84 |
INTRAOPERATIVE
AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION |
| I-85 |
TREATMENT
OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH
AIDS |
| I-86 |
TREATMENT
OF SECONDARY CARNITINE DEFICIENCY |
| I-87 |
RENAL
IMAGING AGENT FOR USE IN CHILDREN |
| I-88 |
MANAGEMENT
OF ENDOMETRIOSIS |
| I-89 |
EPIDURAL
USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO
BUPIVACAINE |
| I-90 |
INTENSIVE
CARE UNIT SEDATION |
| I-91 |
MONOTHERAPY
USE FOR HYPERTENSION |
| I-92 |
ADJUNCTIVE
THERAPY IN THE MANAGEMENT OF HEART FAILURE |
| I-93 |
PREVENTION
OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11
YEARS |
| I-94 |
USE WITH
MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND
FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING
THE HEART] |
| I-95 |
TREATMENT
OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL
INFARCTION |
| I-96 |
TREATMENT
OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA |
| I-97 |
ORAL OR
RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE
GASTROINTESTINAL TRACT |
| I-98 |
TREATMENT
OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH
CHRONIC RENAL INSUFFICIENCY |
| I-99 |
PEDIATRIC
ANESTHESIA IN CHILDREN 3 YEARS AND OLDER |
| I-100 |
TO
DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS
UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE
CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY |
| I-101 |
TREATMENT
OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT
DIABETES MELLITUS AND RETINOPATHY |
| I-102 |
TREATMENT
OF OBSESSIVE-COMPULSIVE DISORDER |
| I-103 |
PROPHYLAXIS
AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO
ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF
DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA |
| I-104 |
TREATMENT
OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS
WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO
AMPHOTERICIN B THERAPY |
| I-105 |
TREATMENT
OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF
FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY |
| I-106 |
TREATMENT
OF ACROMEGALY |
| I-107 |
VAGINAL
CANDIDIASIS |
| I-108 |
EXPANDED
USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING
MECHANICAL VENTILATION |
| I-109 |
TYPHOID
FEVER |
| I-110 |
PREVENTION
OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY |
| I-111 |
TREATMENT
OF PAGET'S DISEASE OF BONE |
| I-112 |
MANAGEMENT
OF MODERATE TO SEVERE PAIN |
| I-113 |
TREATMENT
OF PROSTATITIS |
| I-114 |
USE IN
CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY
IN THE BRAIN (INTRACRANIAL LESIONS), SPINE AND ASSOCIATED
TISSUE |
| I-115 |
USE IN MRI
IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK |
| I-116 |
MAINTENANCE
OF HEALING OF EROSIVE ESOPHAGITIS |
| I-117 |
TO SLOW
THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS
WITH CORONARY HEART DISEASE |
| I-118 |
PREVENTION
OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY
EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY |
| I-119 |
TREATMENT
OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL
IRON THERAPY |
| I-120 |
MAINTENANCE
THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE
AFTER HEALING ACUTE ULCERS |
| I-121 |
EXPANDED
PATIENT POPULATION - USE IN ICU PATIENTS |
| I-122 |
PSORIASIS
OF THE SCALP |
| I-123 |
RELIEF OF
MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER |
| I-124 |
LEUCOCYTE
LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF
INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE |
| I-125 |
EXPANSION
OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT
THERAPEUTIC PROCEDURES |
| I-126 |
ADJUNCT TO
THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO
EXERCISE ADEQUATELY |
| I-127 |
TREATMENT
OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED
PATIENTS |
| I-128 |
IN
PATIENTS WITH CORONARY HEART DISEASE AND
HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL
MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF
NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR
UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES;
REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN
PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND
IIB) |
| I-129 |
TREATMENT
OF ALCOHOL DEPENDENCE |
| I-130 |
MAINTENANCE
OF HEALING OF EROSIVE ESOPHAGITIS |
| I-131 |
PERIPHERAL
ARTERIOGRAPHY |
| I-132 |
TREATMENT
OF MANIC PHASE OF BIPOLAR DISORDER |
| I-133 |
MANAGEMENT
OF CHRONIC STABLE ANGINA |
| I-134 |
HEART
FAILURE POST MYOCARDIAL INFARCTION |
| I-135 |
BONE
METASTASES ASSOCIATED WITH MULTIPLE MYELOMA |
| I-136 |
IDIOPATHIC
CHRONIC URTICARIA |
| I-137 |
PREVENTION
OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR
STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR
BEVERAGES |
| I-138 |
TREATMENT
OF ACUTE RECURRENT GENITAL HERPES |
| I-139 |
PALLIATIVE
TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND
PERIMENOPAUSAL WOMEN |
| I-140 |
PREVENTION
OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV
INFECTION AT RISK FOR DEVELOPING CMV DISEASE |
| I-141 |
TREATMENT
OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF
ACUTE MYOCARDIAL INFRACTION TO IMPROVE SURVIVAL |
| I-142 |
LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT)
AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING
MYOCARDIAL FUNCTION |
| I-143 |
EPISODIC
TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT
ADULTS |
| I-144 |
ENHANCEMENT
OF MRI OF THE ADULT BODY INTERNAL ORGANS |
| I-145 |
0.1MMOL/KG
AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN
CHILDREN |
| I-146 |
CONTRAST
ENHANCEMENT AND FACILITATION OF VISUALIZATION OF
EXTRACRANIAL HEAD AND NECK LESIONS |
| I-147 |
PREVENTION
OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING
RAPID WEIGHT LOSS |
| I-148 |
TREATMENT
OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED
PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2)
IS LESS THAN OR EQUAL TO 55 TORR |
| I-149 |
TREATMENT
OF PATIENTS WITH NON-SMALL CELL LUNG CANCER |
| I-150 |
TREATMENT
OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER |
| I-151 |
PREVENTION
OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND
VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL
ANESTHESIA |
| I-152 |
SLOWING
THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING
THE RISK OF ACUTE CORONARY EVENTS |
| I-153 |
MANAGEMENT
OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL
ORIGIN] |
| I-154 |
PATIENT
POPULATION ALTERED TO INCLUDE PEDIATRIC USE |
| I-155 |
TREATMENT
OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF
THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT |
| I-156 |
ADDITIONAL
DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH
HEART FAILURE |
| I-157 |
TREATMENT
OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES |
| I-158 |
TREATMENT
OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER |
| I-159 |
FOR
HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT
HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION,
REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES
WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES |
| I-160 |
TREATMENT
OF BACTERIAL CORNEAL ULCERS |
| I-161 |
TREATMENT
OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE
DEFICIENCY |
| I-162 |
FOR USE IN
PATIENTS 6-11 YEARS OF AGE |
| I-163 |
TREATMENT
OF PHOTOPHOBIA |
| I-164 |
CHRONIC
BACTERIAL PROSTATITIS |
| I-165 |
MANAGEMENT
OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID
ARTHRITIS WHO HAVE HAD AN INSUFFICIENT THERAPEUTIC
RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF
FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS |
| I-166 |
TREATMENT
OF BULIMIA |
| I-167 |
COMPLICATED
INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH
METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC
PATHOGENS |
| I-168 |
MANAGEMENT
OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF
THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS) |
| I-169 |
USE IN
COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY
FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO
ADVANCED HORMONE-REFRACTORY PROSTATE CANCER |
| I-170 |
PROPHYLACTIC
USE DURING HEAD LICE EPIDEMICS |
| I-171 |
RELIEF OF
SYMPTOMS OF THE COMMON COLD |
| I-172 |
TREATMENT
OF INITIAL EPISODE OF GENITAL HERPES |
| I-173 |
PREOPERATIVELY
FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE
BIOPSY |
| I-174 |
PELVIC
INFLAMMATORY DISEASE |
| I-175 |
TREATMENT
OF TINEA CORPORIS AND TINEA CRURIS |
| I-176 |
TREATMENT
OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE
UNDERGONE CATARACT EXTRACTION |
| I-177 |
TREATMENT
OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO
15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO
ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE
ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE
MEDICATIONS |
| I-178 |
TREATMENT
OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT
ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN |
| I-179 |
NOSOCOMIAL
PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY
HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE |
| I-180 |
TREATMENT
OF PLANTAR TINEA PEDIS (MOCCASIN TYPE) |
| I-181 |
TREATMENT
OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND
WITHOUT SECONDARY GENERALIZATION |
| I-182 |
TREATMENT
OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME |
| I-183 |
MAINTENANCE
THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN
PEDIATRIC PATIENTS AGES 6-11 |
| I-184 |
TREATMENT
OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2
MG/DAY (MAXIMUM OF 4MG) |
| I-185 |
PREVENTION
OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| I-186 |
TREATMENT
OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO
BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS
MALASSEZIA FURFUR OR M. ORBICULARE) |
| I-187 |
PREVENTION OF FRACTURES IN THE TREATMENT OF
POSTMENOPAUSAL OSTEOPOROSIS |
| I-188 |
TREATMENT
OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC
SINUSITIS |
| I-189 |
TREATMENT
OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS |
| I-190 |
PLANAR
IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER
MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS
IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE
BREAST MASS |
| I-191 |
ENDOMETRIAL
THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR
DYSFUNCTIONAL UTERINE BLEEDING |
| I-192 |
THE
PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO
PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL
SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS
INDICATION |
| I-193 |
TREATMENT
OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO
200MG/DAY |
| I-194 |
CONGESTIVE
HEART FAILURE |
| I-195 |
USE OF
LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND
AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN
PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR
HISTORY OF DUODENAL ULCER |
| I-196 |
ACUTE
TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
| I-197 |
MAINTENANCE
OF HEALING OF DUODENAL ULCER |
| I-198 |
USE OF
LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE
ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH
ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A
DUODENAL ULCER |
| I-199 |
MONOTHERAPY
AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE
TREATMENT OF TYPE II DIABETES |
| I-200 |
TREATMENT
OF TINEA (PITYRIASIS) VERSICOLOR |
| I-201 |
EMPIRICAL
THERAPY FOR FEBRILE NEUTROPENIC PATIENTS |
| I-202 |
SECOND-LINE
TREATMENT OF AIDS-RELATED KAPOSI’S SARCOMA |
| I-203 |
MAINTENANCE
OF REMISSION OF ULCERATIVE COLITIS |
| I-204 |
USE IN
PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE
TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL
ALLERGIC RHINITIS |
| I-205 |
INITIAL
ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS |
| I-206 |
TREATMENT
OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE |
| I-207 |
FOR THE
SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN
IMMUNOCOMPETENT ADULTS |
| I-208 |
TREATMENT
OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC
POPULATION |
| I-209 |
PAROXYSMAL
SUPRAVENTRICULAR TACHYCARDIA (PSVT) |
| I-210 |
TO SLOW THE PROGRESSION OF
CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART
DISEASE AS PART OF A TREATENT STRATEGY TO LOWER TOTAL AND
LDL CHOLESTEROL TO TARGET LEVELS |
| I-211 |
FOR USE IN THE PEDIATRIC
POPULATION |
| I-212 |
TREATMENT OF SYMPTOMS OF
DRY MOUTH IN PATIENTS WITH SJOGREN’S SYNDROME |
| I-213 |
TEMPORARY RELIEF OF PAIN
AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE
SURGERY |
| I-214 |
TREATMENT OF OSTEOPOROSIS |
| I-215 |
PRE-PROCEDURAL
APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC
SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL
OF GENITAL WARTS |
| I-216 |
FOR THE LONG-TERM TWICE-DAILY
(MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE
TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING
CHRONIC BRONCHITIS AND EMPHYSEMA |
| I-217 |
PREVENTION (DURING AND
FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH
MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING
HIP REPLACEMENT SURGERY |
| I-218 |
USE OF LIPITOR AS AN
ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS
WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON
TYPE IV) |
| I-219 |
USE OF
LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON
TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET |
| I-220 |
TREATMENT OF EPISODIC
HEARTBURN, ACID INDIGESTION AND SOUR STOMACH |
| I-221 |
TREATMENT OF BENIGN
PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED
PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE
URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF
SURGERY |
| I-222 |
PREVENTION OF ISCHEMIC
COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE
MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED
WITH ASPIRIN |
| I-223 |
USE IN THE SYMPTOMATIC
RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND
NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS |
| I-224 |
FOR THE USE IN PEDIATRIC
PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE
NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC
RHINITIS |
| I-225 |
USE IN PATIENTS WITH
PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK
OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND
CEREBROVASCULAR DISEASE EVENTS |
| I-226 |
FIRST-LINE THERAPY FOR THE
TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN
COMBINATION WITH CISPLATIN |
| I-227 |
SHORT-TERM TREATMENT OF
SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
| I-228 |
PREVENTION OF MEAL INDUCED
HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A
MEAL |
| I-229 |
PRILOSEC (OMEPRAZOLE),
AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H.
PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE |
| I-230 |
IN
COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT
OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT
CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR
RADIATION |
| I-231 |
TREATMENT OF PATIENTS WITH
LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER
FAILURE OF PRIOR CHEMOTHERAPY |
| I-232 |
TREATMENT OF
RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED
PATIENTS AT A DOSE OF 500MG TWICE DAILY |
| I-233 |
PROPHYLACTIC USE TO REDUCE
PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD
TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS
IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY |
| I-234 |
FOR USE IN COMBINATION
WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS
WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR
METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER |
| I-235 |
PREVENTION OF EXERCISE-INDUCED
BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER |
| I-236 |
PREVENTION OF EXERCISE-INDUCED
BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER |
| I-237 |
MAINTENANCE TREATMENT OF
ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS
OF AGE AND OLDER |
| I-238 |
ADJUNCTIVE TREATMENT OF
LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS |
| I-239 |
TREATMENT OF PATIENTS WITH
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| I-240 |
MANAGEMENT OF
SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC
BONE
DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL
FAILURE (Ccr 15 TO 55ML MIN) NOT YET ON DIALYSIS |
| I-241 |
USE IN PHOTODYNAMIC
THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION
OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY
OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER |
| I-242 |
TREATMENT OF MODERATE TO
SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN
WOMEN WITH AN INTACT UTERUS |
| I-243 |
USE IN THE SYMPTOMATIC
RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN
CHILDREN AGE 5 TO 11 YEARS |
| I-244 |
REDUCE THE INCIDENCE OF
BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER |
| I-245 |
TREATMENT OF ACUTE
SINUSITIS |
| I-246 |
TREATMENT OF UNCOMPLICATED
URINARY TRACT INFECTIONS |
| I-247 |
USE IN CONVERSION TO
MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE
RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING
ANTIEPILEPTIC DRUG |
| I-248 |
INPATIENT TREATMENT OF
ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY
EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM
AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS
WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN
CONJUNCITON WITH WARFARIN SODIUM |
| I-249 |
TREATMENT OF CHRONIC
HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE
PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY |
| I-250 |
PRIMARY PREVENTION OF
CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC
CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY
ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C |
| I-251 |
TREATMENT OF GENERALIZED
ANXIETY DISORDER |
| I-252 |
NEW COMBINATION USE OF
PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH
DIET PLUS METFORMIN |
| I-253 |
COMBINATION USE OF PRECOSE
FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS
INSULIN |
| I-254 |
PREVENTION OF
POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS) |
| I-255 |
PREVENTION OF PNEUMOCYSTIS
CARINII PNEUMONIA (PCP) |
| I-256 |
USE IN TREATMENT OF SMALL
CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE
CHEMOTHERAPY |
| I-257 |
TREATMENT OF CHRONIC
HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL
REPLICATION AND ACTIVE LIVER INFLAMMATION |
| I-258 |
FOR PERENNIAL NONALLERGIC
RHINITIS FOR AGES FOUR AND ABOVE |
| I-259 |
PROPHYLAXIS OF DEEP VEIN
THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM,
IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY |
| I-260 |
EXPANDED PEDIATRIC USE IN
CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A
GESTATIONAL AGE OF 37 WEEKS OR GREATER) |
| I-261 |
TREATMENT OF SOCIAL
ANXIETY DISORDER |
| I-262 |
TREATMENT OR PREVENTION OF
BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE
AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM
IN CHILDREN AGES 4-12 |
| I-263 |
TREATMENT OF UNSTABLE
ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE
PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON
CONCURRENT ASPIRIN THERAPY |
| I-264 |
PREVENTION OF NAUSEA AND
VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY
IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION |
| I-265 |
TREATMENT OF ATOPIC
DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER |
| I-266 |
USE OF TOPAMAX AS
ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS
WITH PARTIAL ONSET SEIZURES |
| I-267 |
USE IN PEDIATRIC PATIENTS
3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE
DERMATOSES |
| I-268 |
PROPHYLAXIS AND CHRONIC
TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE |
| I-269 |
PREVENTION OF NAUSEA AND
VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER
CHEMOTHERAPY, INCLUDING CISPLATIN |
| I-270 |
ADJUVANT TREATMENT OF NODE-POSITIVE
BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD
DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY |
| I-271 |
TREATMENT OF OSTEOPOROSIS
IN POSTMENOPAUSAL WOMEN |
| I-272 |
TREATMENT OF
GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN
RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG
OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL
DENSITY |
| I-273 |
ADJUNCT TO DIET TO
INCREASE HDL-C IN PATIENTS WITH PRIMARY
HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND
NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES
IIA AND IIB) |
| I-274 |
USE OF TOPAMAX AS
ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY
GENERALIZED TONIC-CLONIC SEIZURES |
| I-275 |
USE IN COMBINATION WITH
METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2
DIABETES |
| I-276 |
USE OF REZULIN IN
COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS
WITH TYPE 2 DIABETES |
| I-277 |
TREATMENT OF TYPE III
HYPERLIPOPROTEINEMIA |
| I-278 |
TREATMENT OF PATIENTS WITH
ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV) |
| I-279 |
TREATMENT OF POST-TRAUMATIC
STRESS DISORDER |
| I-280 |
USE OF CARNITOR INJECTION
FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY
IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE
UNDERGOING DIALYSIS |
| I-281 |
INCREASING HDL-C IN
PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS
FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON
TYPES IIa and IIb) |
|
